Aneurysmal Subarachnoid Hemorrhage Clinical Trial
Official title:
EARLYdrain - Prospective Outcome Study of Early Lumbar Drainage in Aneurysmal Subarachnoid Hemorrhage
The intention of the study is to investigate whether drainage of cerebral spinal fluid via a lumbar route ("Tuohy-drain") will improve outcome after intracranial aneurysmal subarachnoid hemorrhage (SAH).
1. Introduction
Patients suffering from aneurysmal subarachnoid hemorrhage (SAH) are predominantly
threatened by two distinct medical problems. Firstly, they may experience a second -
and often more severe - hemorrhage, and secondly, they may suffer a constringence
reaction of the vessels supplying the brain with blood, called vasospasm.
The first problem is resolved by rapid cerebrovascular imaging and subsequent treatment
of the ruptured aneurysm, thus preventing recurrent hemorrhage. Aneurysm treatment may
be performed either via craniotomy and surgical clipping of the aneurysm or with
endovascular techniques by occluding the aneurysm with small platinum coils.
The vasospasm - the second problem - is more difficult to handle. A hypothesis is that
the development of vasospasm is related to the amount of blood in the basal cisterns.
Therefore, a possible strategy tries to remove this blood as much as possible. Excess
removal of cerebral spinal fluid (CSF) via an external ventricular drain fails in
preventing vasospasm and may lead to a higher incidence of posthemorrhagic shunt
dependency. Reason is that after aneurysmal SAH, the blood is packed more densely in
the basal cisterns and therefore only CSF, being more lightweight, is drained from the
ventricles. As an alternative approach, application of a lumbar drain is proposed to
address clotting of the blood in the basal cisterns. Three retrospective studies in
patients after aneurysmal SAH, the newest being available only as abstract, were able
to establish the safety of this approach (Klimo et al, Kwon et al, Tizi et al (abstract
DGNC 2009)). One of the fully published studies addressed vasospasm prophylaxis after
surgical clipping, while the other was performed in patients after endovascular
coiling. All studies led to a markedly diminished incidence of angiographic vasospasm.
Therefore, a prospective study addressing the efficacy of this novel therapeutic
approach is warranted.
The focus of the EARLYDRAIN study is to examine the efficacy of application of lumbar
drainage in patients with acute subarachnoidal hemorrhage from a cerebral aneurysm.
Hypothesis is that early application of lumbar drainage after aneurysmal SAH leads to a
diminished incidence of cerebral vasospasm, as assessed by digital subtraction
angiography, and an improved outcome, measured by the modified Rankin score, at six
months.
2. Study outline
Patients suffering from aneurysmal SAH are treated according to international
standards. Aneurysm treatment is at the discretion of the neurovascular team taking
care for a patient and not specified by the study protocol. All medical treatment is
performed according to local guidelines and standard operating procedures.
Any patient meeting the inclusion criteria and not violating the exclusion criteria may
participate in the EARLYDRAIN study and be randomized to either receive a lumbar drain
or not, thus defining the two distinct groups LD and NoLD. To prevent premature rupture
of the aneurysm due to accidental drainage, randomization to the study and eventual
placement of a lumbar drain takes place after securing the aneurysm by the preferred
method of choice. Any patient in the LD group receives a lumbar drain during anesthesia
required for aneurysm treatment. This is to be performed before anticoagulation or
anti-platelet therapy is initiated, which sometimes is warranted after endovascular
coiling. A post-procedural CCT scan of the brain is performed within to 24 hours of
aneurysm treatment. In case of any neurological worsening after the procedure it is
strongly recommended to perform the follow-up CCT scan as soon as possible.
In patients in the LD group, CSF drainage is started via LD slowly and steadily at a
rate of approximately 5 ml per hour after the post-interventional CCT. This leads to a
planned daily CSF drainage of about 120 ml per day via lumbar route. Patients in both
groups may receive additional CSF drainage via a ventricular device as required. The
amount of CSF drained via ventricular route is according to clinical requirement and
not specified.
To facilitate accuracy of drainage, regular drainage control every other hour and
stopping in case of excess drainage is strongly recommended by the principal
investigators. In case of neurological decline suspiciously related to the lumbar
drainage, the drain is closed immediately and may be gradually restarted after 12 to 24
hours, after performing a CCT scan.
If the post-procedural CCT or any other follow-up CCT scan shows absent basal cisterns
or any signs of threatening herniation, lumbar CSF diversion in the LD group shall not
be performed. It may still be feasible to carefully drain CSF via the lumbar route may
(Tuettenberg et al), but this is at the discretion of the local investigator and not
recommended.
In patients requiring sedation and mechanical ventilation, either due to neurological
impairment or otherwise, intracranial pressure monitoring is mandatory. This may be
performed according to local policy either with parenchymal or ventricular devices. If
the intracranial pressure exceeds 20 mmHg, further CSF drainage via lumbar route shall
be interrupted until the ICP is below 20 mmHg again. Careful CSF drainage via the
lumbar route may be still feasible in case of high intracranial pressure (Tuettenberg
et al), but is at the discretion of the local investigator.
Further neuromonitoring with TCD, EEG, brain tissue oxygenation, jugular bulb oxymetry,
regional cerebral blood flow, microdialysis or other devices is at the discretion of
the center and according to its local guidelines. As far as possible, this data should
be saved electronically for post-hoc analysis.
A CCT scan as well as conventional digital subtraction angiography, CT angiography or
MR angiography for assessment of vasospasm in the larger vessels is routinely performed
on day 7 to 10 after the initial hemorrhage, regardless of the patient condition. In
case of clinical suspicion of vasospasm, angiography may be performed at any time. If
it is performed earlier and the patient shows no clinical deterioration thereafter, the
angiography on day 7 to 10 is omitted.
After cerebrovascular imaging on day 7 to 10, or day 8 in case of an earlier
angiography, the lumbar drainage of CSF is stopped in the LD group. It may be pursued
on a clinical base, as required.
Amount and duration of CSF drainage Patients randomized to the lumbar drainage group
shall receive a daily drainage of 120 ml CSF, or 5 ml per hour for seven days. If
higher amounts of CSF need to be drained on clinical grounds as in patients with
hydrocephalus, this is preferably performed via external ventricular drain.
The drain is planned to remain in place until the control angiography on day 7 to 10
after the initial hemorrhage. The local investigator may decide to remove the drain
earlier in patients fully mobilized without clinical necessity of CSF drainage.
However, consecutive drainage should not be less than four days to achieve a valid
study result. Lumbar CSF drainage may be prolonged beyond the control angiography on
clinical requirement. The amount of CSF drainage may then be adjusted to clinical needs
and bears no further restriction.
Patients randomized to the control group should not receive a lumbar drain before the
planned control angiography to be performed on day 7 to 10 after SAH. If the patient
develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar
drain may be installed at the discretion of the local investigator. These patients are
analyzed in the intention-to-treat analysis, but are not suitable for per-protocol
analysis.
3. Consent to the study
Consent for study inclusion is sought after explanation and agreement to a specific
aneurysm treatment. Thus, patients capable of consenting to the aneurysm treatment get
the study details explained themselves and may or may not agree to participate. If a
patient is incapable for consenting to the proposed treatment, the legal representative
should be informed on the conditions of treatment choices and afterwards, on the
details of the EARLYDRAIN study. A patient may be randomized if the legal
representative gives informed consent to the study, based on the presumed will of the
patient. If neither the patient is capable of giving informed consent nor a legal
representative is available in due time, an independent physician not involved in the
patient's treatment nor in the trial may be asked for study approval. In these cases of
deferred consent, a legal representative needs to be established as soon as possible,
according to German law. As soon as a legal representative is available and/or the
patient is capable again to consent to the study, he or she must be asked to give
informed consent. If the patient or his/her legal representative refuses consent after
inclusion by advice of an independent physician, no further study participation of the
patient is possible. In this case, however, the patient or his/her legal representative
are asked to give consent for evaluation of already acquired data.
4. Safety of lumbar drains after aneurysmal SAH
In all three retrospective studies, mortality was lower in the lumbar drainage group.
None of the retrospective studies mentions procedural related complications for the
lumbar drains (Klimo et al, Kwon et al, Tizi et al (abstract at the DGNC 2009)). In
patients with increased intracranial pressure, careful lumbar drainage of CSF may be a
possible treatment even in case of compressed basal cisterns (Tuettenberg et al). To
date, there is no data available indicating an increased risk of lumbar drainage in a
controlled neurointensive care environment.
5. Insurance coverage
As the EARLYDRAIN study compares two standard procedures of CSF drainage after subarachnoid
hemorrhage used in clinical routine, no additional patient insurance is necessary to perform
the study. German laws §§ 40 to 42 Arzneimittelgesetz or §§ 20 to 23 Medizinproduktegesetz
are not applicable. Any hypothetical adverse events of either treatment are covered by the
regular treatment contracts which do include clinical research.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03209830 -
Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Not yet recruiting |
NCT03271697 -
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
|
Phase 2/Phase 3 | |
Recruiting |
NCT01098890 -
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT00692744 -
Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)
|
N/A | |
Active, not recruiting |
NCT05738083 -
Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
|
||
Completed |
NCT03754335 -
SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture
|
N/A | |
Completed |
NCT06076590 -
Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study
|
Phase 4 | |
Recruiting |
NCT04548401 -
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
|
||
Terminated |
NCT04148105 -
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 4 | |
Recruiting |
NCT06329635 -
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
|
N/A | |
Recruiting |
NCT02129413 -
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
|
N/A | |
Terminated |
NCT00487461 -
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06288659 -
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
|
N/A | |
Recruiting |
NCT05974111 -
COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
|
||
Recruiting |
NCT03706768 -
Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06284642 -
Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)
|
Phase 4 | |
Recruiting |
NCT01773200 -
Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Completed |
NCT02026596 -
SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage
|
N/A |